Option chain shows key data for TC BioPharm (Holdings)'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TC BioPharm (Holdings).

TC BioPharm (Holdings) (NASDAQ:TCBPW) Stock, Option Chain

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

TC BioPharm Doses First 3 Patients in Phase 2b Clinical Trial of Lead Compound, OmnImmune®, To Treat Acute Myeloid Leukemia

Biotech

News

Penny Stocks

General

TCBP

TCBPW

TC Biopharm (NASDAQ: TCBP) (NASDAQ: TCBPW) recently announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®, 

TC BioPharm (Holdings) PLC

Financing

Offerings

PHIO

Phio Pharmaceuticals Agreed To A Registered Direct Offering Of 833,335 Shares Priced At $3.00 Per Share. Concurrent Private Placement, The Company Will Issue Short-term Unregistered Warrants To Purchase Up To 1.7M Shares

Janney Montgomery Scott analyst Robert Stevenson upgrades Center (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSR#NYSE">CSR</a>) from Neutral to Buy.

Upgrades

Analyst Ratings

Janney Montgomery Scott Upgrades Center to Buy

Quantum computing stocks saw a significant uptick during pre-market trading on Wednesday, driven by Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) entering the quantum computing conversation with plans to make its business clients &#8220;quantum-ready&#8221; by 2025.
What Happened:&nbsp;According to&nbsp;<a href="https://pro.benzinga.com/">Benzinga Pro</a>,&nbsp;Quantum Computing Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) surged by 12.38%,&nbsp;Rigetti Computing Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) increased by 3.02%, and&nbsp;D-Wave Quantum Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) climbed by 12.05%.
Microsoft emphasized the importance of preparing for the technological advancements expected in the coming year. It stated in a blog post, "We are at the advent of the reliable quantum computing era. And we are right on the cusp of seeing quantum computers solve meaningful problems and capture new business value."
The company anticipates that&nbsp;the pace of quantum research&nbsp;and development will accelerate, urging business leaders to act promptly.
Despite the optimism, skepticism remains.&nbsp;Nvidia Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang, during a&nbsp;recent CES technology trade show,&nbsp;predicted that practical quantum computing applications might still be 15 years away. Leading scientists echo this sentiment, suggesting a longer timeline for economically useful quantum computers.
Why It Matters: The recent surge in<a href="https://www.benzinga.com/markets/equities/25/01/42939766/quantum-computing-stocks-tumble-after-mark-zuckerberg-backs-nvidia-ceo-jensen-huangs-practical-comments-qubt-down-9-rgti-falls-16-and-ionq-loses-15"> quantum computing stocks</a> comes on the heels of a downturn earlier this week. On Monday, stocks like&nbsp;Quantum Computing and&nbsp;Rigetti Computing experienced declines following comments from&nbsp;Meta&nbsp;CEO Mark Zuckerberg. Both leaders expressed caution regarding the timeline for quantum computing advancements, which led to a drop in stock prices.
Despite Huang&#8217;s prediction of a 15 to 30-year timeline for practical quantum computing,&nbsp;<a href="https://www.benzinga.com/markets/equities/25/01/42966492/jensen-huang-said-quantum-computing-is-20-years-away-but-nvidia-bets-big-on-strategic-hiring">Nvidia is actively investing</a> in its quantum computing capabilities, hiring for roles that will support this future technology. This strategic move indicates a long-term commitment to integrating quantum and classical computing systems.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/01/42988617/jpmorgan-vs-wells-fargo-1-stock-technically-stronger-ahead-of-earnings">JPMorgan Vs. Wells Fargo: 1 Bank Stock Technically Stronger Ahead Of Earnings</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

MSFT

NVDA

QBTS

QUBT

RGTI

QUBT, QBTS Up 12%, RGTI Gains 3% In Wednesday Premarket: Quantum Computing Stocks Gain Momentum After Microsoft Says 'We Are Right On The Cusp Of Seeing Quantum Computers Solve Meaningful Problems'

<h3>Gainers</h3>
<ul>
<li>Vision Marine Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) shares moved upwards by 64.3% to $2.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.5 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) stock moved upwards by 22.98% to $1.98. The market value of their outstanding shares is at $27.2 million. </li>
<li>Motorcar Parts of America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPAA#NASDAQ">MPAA</a>) shares increased by 10.84% to $6.95. The company's market cap stands at $137.9 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) shares increased by 10.04% to $5.26. The company's market cap stands at $60.4 million. </li>
<li>Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) shares moved upwards by 10.0% to $8.58. The market value of their outstanding shares is at $106.0 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) shares rose 9.72% to $0.64. The market value of their outstanding shares is at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Homestolife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLM#NASDAQ">HTLM</a>) shares decreased by 31.0% to $5.21 during Wednesday's pre-market session. The market value of their outstanding shares is at $76.5 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) stock fell 27.63% to $0.06. The market value of their outstanding shares is at $5.3 million. </li>
<li>Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) shares fell 9.02% to $11.6. The market value of their outstanding shares is at $358.7 million. </li>
<li>MGO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares decreased by 5.48% to $0.55. The market value of their outstanding shares is at $2.4 million. </li>
<li>Bally's Corporation Common Stock (Rolling Shares) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) shares declined by 5.36% to $18.75. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares decreased by 5.24% to $1.81. The company's market cap stands at $1.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BALY

EZGO

HTLM

LGCY

MGOL

MPAA

NAAS

RIME

SPHL

VMAR

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

WIIM

COMP

Compass shares are trading higher after the company raised its Q4 and FY24 guidance.

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares moved upwards by 32.6% to $0.92 during Wednesday's pre-market session. The company's market cap stands at $3.4 million. </li>
<li>Climb Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLYM#NASDAQ">CLYM</a>) stock increased by 19.25% to $2.23. The market value of their outstanding shares is at $150.0 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares moved upwards by 15.42% to $9.95. The market value of their outstanding shares is at $30.2 million. </li>
<li>Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) stock increased by 14.67% to $1.25. The company's market cap stands at $53.7 million. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) shares increased by 11.36% to $0.98. The company's market cap stands at $65.4 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares moved upwards by 11.09% to $1.1. The market value of their outstanding shares is at $82.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock fell 29.1% to $0.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.2 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock fell 23.2% to $0.09. The company's market cap stands at $1.5 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 20.2% to $0.83. The market value of their outstanding shares is at $129.9 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares fell 15.19% to $1.62. The company's market cap stands at $4.5 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock declined by 14.53% to $3.06. The company's market cap stands at $5.3 million. </li>
<li>Ardent Health Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) stock declined by 14.52% to $12.01. The market value of their outstanding shares is at $1.7 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARDT

AZTR

CLYM

CNTX

GBIO

GCTK

HSDT

RPID

TOVX

XCUR

ZJYL

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Under the terms of the Merger Agreement, Amplify will issue Juniper approximately 26.7 million shares of Amplify common stock(1), par value $0.01 per share, and assume approximately $133 million in net debt(2). Pro forma for the Transaction, Amplify shareholders will retain approximately 61% of Amplify's outstanding equity and approximately 39% will be owned by Juniper. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions, including obtaining the requisite shareholder and regulatory approvals.

AMPY

Amplify Energy Inks Definitive Merger Agreement With Juniper Capital: Amplify Will Issue Juniper Approximately 26.7M Shares Of Amplify Common Stock, Par Value $0.01 Per Share, And Assume Approximately $133M In Net Debt

<h3>Gainers</h3>
<ul>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock rose 107.4% to $1.12 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. </li>
<li>Li Bang International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBGJ#NASDAQ">LBGJ</a>) shares increased by 12.82% to $3.08. The market value of their outstanding shares is at $57.7 million. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares moved upwards by 11.57% to $1.35. The company's market cap stands at $20.1 million. </li>
<li>Richtech Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) stock increased by 8.84% to $2.83. The company's market cap stands at $268.3 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) stock rose 7.87% to $1.37. The company's market cap stands at $24.6 million. </li>
<li>Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) shares rose 7.14% to $7.35. The company's market cap stands at $244.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Li-Cycle Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) shares fell 17.1% to $1.26 during Wednesday's pre-market session. The company's market cap stands at $34.6 million. </li>
<li>Staffing 360 Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares decreased by 10.76% to $2.49. The market value of their outstanding shares is at $3.8 million. </li>
<li>Nocera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) stock declined by 10.28% to $0.96. The market value of their outstanding shares is at $13.4 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock fell 8.07% to $0.29. The market value of their outstanding shares is at $16.2 million. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) stock declined by 5.65% to $0.65. The market value of their outstanding shares is at $18.9 million. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) stock decreased by 5.56% to $1.02. The company's market cap stands at $22.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTG

CLIK

GLXG

LBGJ

LICY

Nuveen Insured California Premium Fund Ii

NCRA

OMEX

SFHG

SGBX

STAF

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares rose 15.8% to $2.86 during Wednesday's pre-market session. The company's market cap stands at $19.9 million. </li>
<li>908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) shares moved upwards by 14.14% to $2.26. The company's market cap stands at $78.6 million. </li>
<li>D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares rose 13.74% to $5.38. The market value of their outstanding shares is at $1.4 billion. </li>
<li>AXT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXTI#NASDAQ">AXTI</a>) stock moved upwards by 11.27% to $2.27. The market value of their outstanding shares is at $101.5 million. </li>
<li>Semilux International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELX#NASDAQ">SELX</a>) stock rose 10.6% to $1.81. The company's market cap stands at $67.7 million. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) stock moved upwards by 10.49% to $8.21. The company's market cap stands at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LGL Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGL#AMEX">LGL</a>) stock decreased by 22.5% to $5.0 during Wednesday's pre-market session. The company's market cap stands at $26.8 million. </li>
<li>Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) shares declined by 9.52% to $7.7. The market value of their outstanding shares is at $86.2 million. </li>
<li>Logility Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) shares decreased by 8.75% to $9.81. The market value of their outstanding shares is at $330.4 million. </li>
<li>CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) stock declined by 7.41% to $5.5. The market value of their outstanding shares is at $739.9 million. </li>
<li>eGain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGAN#NASDAQ">EGAN</a>) stock fell 7.11% to $6.01. The company's market cap stands at $171.4 million. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock declined by 6.69% to $0.41. The market value of their outstanding shares is at $21.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXTI

CINT

CODA

EGAN

GRYP

LGTY

MASS

Next Technology Holding Inc. - Ordinary Shares

NXTT

SELX

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

Guidance

Compass Raises FY24 Revenue Guidance From $5.47B-$5.57B To $5.61B-$5.64B

Compass Raises Q4 Revenue Guidance From $1.225B-$1.325B To $1.36B-$1.39B vs $1.294B Est.

PMNT

Perfect Moment Says It Expanded Global Reach With New Leading Luxury Brand Sales Agencies In Europe

BlackRock&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NASDAQ">BLK</a>) Head of Digital Assets, Robert Mitchnick, on Wednesday said that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) adoption is still in its &#8220;early days&#8221;, particularly within the wealth advisory <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42644568/institutional-crypto-adoption-for-real-this-time-says-messari">and institutional segments.</a>
What Happened: He shared this perspective during an <a href="https://www.bloomberg.com/news/videos/2025-01-14/ibit-mstr-draw-different-investor-types-mitchnick-video">interview</a> with Bloomberg, discussing the firm&#8217;s focus for the second year of their IBIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) ETF.
Mitchnick acknowledged that the first year of IBIT saw record-setting inflows and asset accumulation.
He highlighted that BlackRock is still prioritizing its role as a resource and education partner for clients.
The firm specifically targets wealth advisors and institutions, which it believes hold the key to long-term adoption.
Mitchnick stated that the direct end investor demand was &#8220;gangbusters out of the gates&#8221;, but the wealth advisory and institutional segments are yet to see full adoption due to higher hurdles, including more thorough diligence and approval processes.
He noted that while both wealth advisory and institutional channels present significant opportunities, the wealth advisory channel is currently showing the most momentum. 
Firms are working through expedited approvals to allow their advisors to add Bitcoin ETPs to client portfolios.
Mitchnik pointed out that although institutional adoption is moving slowly, BlackRock is &#8220;starting to see more of them emerge&#8221;, particularly in the last quarter of the year.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42985098/gary-gensler-defends-sec-legacy-we-focused-on-reforms-in-the-60-trillion-equity-markets">Gary Gensler Defends SEC Legacy: &#8216;We Focused On Reforms In The $60 Trillion Equity Markets&#8217;</a>
Why It Matters: Mitchnick&#8217;s comments suggest that while initial enthusiasm for Bitcoin ETFs has been strong, the long-term growth and <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42996138/new-crypto-accounting-rules-could-accelerate-corporate-bitcoin-adoption-says-ceo-of-leading-btc-miner-mark-to-market-standards-really-important">mainstream adoption</a> of Bitcoin will require deeper engagement with wealth advisors and institutional investors, and the market remains at a very early stage of maturity.
While BlackRock CEO Larry Fink has shifted from being a Bitcoin skeptic to <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41323418/blackrock-ceo-larry-fink-says-bitcoin-other-cryptos-have-bright-future-regardless-of-wheth">embracing its potential</a> in recent years, JPMorgan Chase CEO Jamie Dimon has held firm in <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42869884/jamie-dimon-questioned-bitcoins-21-million-cap-years-before-blackrock-heres-how-much-youd-have-if-you-invested-1000-into-btc-when-jpmorgan-ceo-shared-his-take">his opposition</a>.
Despite his personal views, JPMorgan has capitalized on Bitcoin's integration into financial products, including its role as an authorized participant for BlackRock's spot Bitcoin ETF.
For instance, speaking with CBS News on Tuesday, Dimon <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42940832/jamie-dimon-says-hes-not-against-blockchains-but-trades-guns-on-bitcoin-again-it-has-no-intrinsic-value-i-just-dont-feel-great-about">reiterated his long-standing criticism</a>, stating, "Bitcoin itself lacks intrinsic value. It is heavily used in activities such as money laundering, ransomware, and human trafficking, which makes me uncomfortable with it."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42982920/microstrategy-plans-perpetual-preferred-stock-offering-to-bolster-bitcoin-strategy">MicroStrategy Plans Perpetual Preferred Stock Offering To Bolster Bitcoin Strategy</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

IBIT

Bitcoin Adoption Still Early, BlackRock Says

This agreement will see Plug supplying three gigawatts (GW) of electrolyzer capacity to AGA's state-of-the-art green hydrogen-to-ammonia plant, currently under development in Australia.
AGA will install a 4.5 GW solar plant to power the Plug electrolyzers with zero emission clean electricity. The green hydrogen produced will be used to make green ammonia.

Contracts

PLUG

Plug Power Enters Purchase Agreement With Allied Green Ammonia For Mega 3 GW Electrolyzer System

Events

NTRA

Natera To Provide Roadmap And Outlook At  J.P. Morgan Healthcare Conference

Needham analyst Scott Berg reiterates Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Buy and maintains $50 price target.

Price Target

Reiteration

BRZE

Needham Reiterates Buy on Braze, Maintains $50 Price Target

CSIQ

Canadian Solar Says It Opened New and Expanded Global Headquarters in Ontario, Canada

In the preceding three months, 5 analysts have released ratings for TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for TG Therapeutics, presenting an average target of $45.0, a high estimate of $55.00, and a low estimate of $22.00. This current average reflects an increase of 16.88% from the previous average price target of $38.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1736942454_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive TG Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tara Bancroft</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to TG Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TG Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of TG Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into TG Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TGTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TG Therapeutics analyst ratings.</a>
<h2>About TG Therapeutics</h2>
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
<h3>Unraveling the Financial Story of TG Therapeutics</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining TG Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -49.41% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.63%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): TG Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): TG Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.79%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.32, TG Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TGTX

Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts

During the last three months, 4 analysts shared their evaluations of Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $34.5, a high estimate of $38.00, and a low estimate of $32.00. This current average has decreased by 4.17% from the previous average price target of $36.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736942446_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Weyerhaeuser. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hamir Patel</td>
<td>CIBC</td>
<td>Announces</td>
<td>Outperformer</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Weyerhaeuser. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Weyerhaeuser compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Weyerhaeuser's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Weyerhaeuser's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Weyerhaeuser analyst ratings.</a>
<h2>Unveiling the Story Behind Weyerhaeuser</h2>
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
<h3>Understanding the Numbers: Weyerhaeuser's Finances</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Weyerhaeuser's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -16.86% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Weyerhaeuser's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.67%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Weyerhaeuser's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.28%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Weyerhaeuser's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.17%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Weyerhaeuser adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Weyerhaeuser Stock: Analyst Perspectives (4 Ratings)

Ratings for Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $212.22, a high estimate of $240.00, and a low estimate of $180.00. Observing a 9.43% increase, the current average has risen from the previous average price target of $193.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1736942439_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Paylocity Holding is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jared Levine</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$228.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jared Levine</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$203.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$212.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$187.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Paylocity Holding. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Paylocity Holding compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Paylocity Holding's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PCTY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Paylocity Holding analyst ratings.</a>
<h2>Discovering Paylocity Holding: A Closer Look</h2>
Paylocity is a provider of payroll and human capital management solutions servicing small- to midsize clients in the United States. The company was founded in 1997 and targets businesses with 10-5,000 employees and services about 39,000 clients as of fiscal 2024. Alongside core payroll services, Paylocity offers HCM solutions such as time and attendance and recruiting software as well as workplace collaboration and communication tools.
<h3>Paylocity Holding's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Paylocity Holding's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -12.5% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Paylocity Holding's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Paylocity Holding's ROE stands out, surpassing industry averages. With an impressive ROE of 3.23%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Paylocity Holding's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.83% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

TC BioPharm (Holdings)

TC BioPharm (Holdings) (TCBPW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga